April 25, 2017, Vol 317, No. 16, Pages 1595-1700
Immunogenicity of 2 vs 3 Doses of the Quadrivalent Human Papillomavirus Vaccine in Girls Aged 9 to 13 Years After 60 Months
Gina Ogilvie, MD, MSc, FCFP, DrPH; Chantal Sauvageau, MD, MSc, FRCPC; Marc Dionne, MD, MPH; et al.
JAMA. 2017;317(16):1687-1688. doi:10.1001/jama.2017.1840
This study uses long-term follow-up clinical trial data to compare antibody response 60 months after girls younger than 15 years were randomized to 2 vs 3 doses of quadrivalent human papillomavirus vaccine.